Epigenetic biomarkers associated with anti-TNF drugs response in moderate-to- severe psoriasis

Abstract

It has recently been discovered that epigenetic modifications, specially DNA methylation, participates in the pathology of psoriasis. DNA methylation is a covalent modification dynamic and heritable that takes place in Cytosine-Phosphate-Guanine (CpG) sites and may exert transcriptional effects. Although anti-tumour necrosis factor α (TNF) therapies (adalimumab, etanercept and infliximab) are efficient drugs for moderate-to-severe psoriasis, around 30–50% of psoriasis patients present an inadequate response.

This article is protected by copyright. All rights reserved.

http://ift.tt/2oeOTbc